SNNUF
SMITH & NEPHEW PLC
$15.10
0.00%
No data for this timeframe.
Vol
SEC Reports10
Exchange OTC·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·CIK 0000845982·Prev Close $15.10
Recent Activity
Jun 4, 2026
SEC
Smith & Nephew filed a 6-K reporting routine insider share purchases by the CEO and three PDMRs through the Employee Sto
6-K — Impact 2/10
Jun 3, 2026
SEC
Smith & Nephew filed a routine 6-K disclosing that several directors and PDMRs purchased ordinary shares through the com
6-K — Impact 1/10
Jun 3, 2026
SEC
Smith & Nephew plc filed a 6-K announcing the admission to trading of EUR 500,000,000 of 4.250% Notes due 2038 on the Lo
6-K — Impact 2/10
Analyst Ratings
6Strong Buy
7Buy
11Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 9 neutral. Avg impact: 2.3/10.
NEUTRAL
6-K
2/10
Smith & Nephew filed a 6-K reporting routine insider share purchases by the CEO and three PDMRs thro
Jun 4, 2026
NEUTRAL
6-K
1/10
Smith & Nephew filed a routine 6-K disclosing that several directors and PDMRs purchased ordinary sh
Jun 3, 2026
NEUTRAL
6-K
2/10
Smith & Nephew plc filed a 6-K announcing the admission to trading of EUR 500,000,000 of 4.250% Note
Jun 3, 2026
NEUTRAL
6-K
2/10
Smith & Nephew disclosed the vesting of conditional share awards under its Global Share Plan 2020 fo
May 20, 2026
BULLISH
6-K
7/10
Cevian Capital II GP Limited disclosed an increased stake in Smith & Nephew PLC, crossing the 11% th
May 14, 2026
NEUTRAL
6-K
1/10
Smith & Nephew filed a 6-K confirming the sterling equivalent of its previously announced final divi
May 12, 2026
NEUTRAL
6-K
1/10
Smith & Nephew filed a routine 6-K disclosing its total voting rights and share capital as of April
May 1, 2026
NEUTRAL
6-K
3/10
Smith & Nephew plc disclosed the grant of 50 ordinary shares to each of 12 senior executives, includ
Apr 16, 2026
NEUTRAL
6-K
2/10
Smith & Nephew plc announced that Thérèse Esperdy, Senior Independent Director designate, will join
Apr 15, 2026
NEUTRAL
6-K
2/10
Smith & Nephew plc filed a 6-K disclosing its total voting rights and share capital as of March 31,
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 54% buy across 24 analysts — 6 strong buy, 7 buy, 11 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.5B | 6.7% | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.6B | 5.4% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $6.6B | 6.7% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.0B | 5.7% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| May 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Apr 1, 2026 | 6 | 6 | 11 | 1 | 0 | 50% | |
| Mar 1, 2026 | 7 | 6 | 10 | 1 | 0 | 54% | |
| Feb 1, 2026 | 7 | 7 | 10 | 0 | 0 | 58% | |
| Jan 1, 2026 | 7 | 6 | 11 | 0 | 0 | 54% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.